$37.65
+7.9%Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
RAPP • NASDAQ
| Rapport Therapeutics, Inc. Common Stock Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
ASSETS | ||||
CURRENT ASSETS | ||||
52.6M | 56.8M | 70.2M | 31.2M | |
437.9M | 248.5M | 77.3M | 0.0 | |
490.5M | 305.3M | 147.5M | 31.2M | |
0.0 | 0.0 | 0.0 | 109K | |
8M | 4.5M | 3.4M | 0.0 | |
498.6M | 309.8M | 150.9M | 31.3M | |
NON-CURRENT ASSETS | ||||
12.9M | 5M | 4M | 335K | |
985K | 160K | 551K | 0.0 | |
13.9M | 5.1M | 4.6M | 335K | |
512.4M | 314.9M | 155.4M | 31.6M | |
LIABILITIES | ||||
CURRENT LIABILITIES | ||||
4.2M | 2M | 2.5M | 1.5M | |
4.2M | 2M | 2.5M | 1.5M | |
0.0 | 2.4M | 3.2M | 213K | |
2.8M | 0.0 | 0.0 | 0.0 | |
0.0 | 737K | 670K | 0.0 | |
12.1M | 3.7M | 2.4M | 0.0 | |
19M | 8.8M | 8.8M | 1.7M | |
NON-CURRENT LIABILITIES | ||||
8.7M | 0.0 | 0.0 | 10.4M | |
0.0 | 0.0 | 170.8M | 0.0 | |
8.7M | 739K | 172.3M | 10.4M | |
0.0 | 1.5M | 2.1M | 0.0 | |
27.8M | 9.5M | 181.1M | 12.1M | |
SHAREHOLDERS' EQUITY | ||||
0.0 | 0.0 | 0.0 | 29.6M | |
48K | 37K | 4K | 31K | |
719.3M | 429.7M | 19.8M | 559K | |
-235.2M | -123.7M | -45.4M | -10.7M | |
546K | -522K | 4K | 0.0 | |
484.7M | 305.4M | -25.6M | 19.5M | |
484.7M | 305.4M | -25.6M | 19.5M | |
SUMMARY | ||||
512.4M | 314.9M | 155.4M | 31.6M | |
437.9M | 248.5M | 77.3M | 0.0 | |
11.5M | 1.5M | 2.1M | 10.4M | |
-41.2M | -55.3M | -68M | -20.7M | |
36,497,618 | 36,497,618 | 36,497,618 | 36,497,618 |
RAPP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 |
Continue your RAPP research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.